Michael Ramos
Family Medicine · Lawton, OKNPI 1063407781
Payments from drug & device makers
Across 80 payments — averaging $15.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$210
- Merck$203
- Teva Pharmaceuticals USA, Inc.$115
- Pfizer$87
- AbbVie$86
- Xeris Pharmaceuticals, Inc.$73
- plus $471 from 14 others
What the payments were for
- Food & beverage$1,244100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 13 | $210 |
| Merck | 21 | $203 |
| Teva Pharmaceuticals USA, Inc. | 6 | $115 |
| Pfizer | 7 | $87 |
| AbbVie(2 entities) | 5 | $86 |
| Xeris Pharmaceuticals, Inc. | 4 | $73 |
| Stimwave Technologies Incorporated | 1 | $64 |
| Aimmune Therapeutics, Inc. | 3 | $58 |
| Abbott | 3 | $55 |
| Novo Nordisk | 3 | $53 |
| Lilly USA, LLC | 2 | $44 |
| GSK | 2 | $32 |
| Exact Sciences | 2 | $29 |
| Genentech USA, Inc. | 2 | $28 |
| Grifols USA, LLC | 1 | $21 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $21 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| Amgen | 1 | $16 |
| Antares Pharma, Inc. | 1 | $16 |
| AstraZeneca | 1 | $15 |
How this compares
$1,244 in reported general payments places this provider in the 65th percentile of 1,730 family medicine providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 94 | $95,961 |
| JanuviaSitagliptin Phosphate | 84 | $74,985 |
| OxycontinOxycodone Hcl | 23 | $47,042 |
| EliquisApixaban | 43 | $33,304 |
| JardianceEmpagliflozin | 35 | $29,368 |
| MounjaroTirzepatide | 12 | $16,429 |
| TrulicityDulaglutide | 11 | $10,153 |
| MyrbetriqMirabegron | 21 | $10,084 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $9,078 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 38 | $6,797 |
| BelbucaBuprenorphine Hcl | 12 | $4,939 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 221 | $4,892 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $4,875 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 104 | $3,814 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 122 | $3,658 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $53 | $95,96194 claims |
| MerckJanuvia | $203 | $74,98584 claims |
| PfizerEliquis, Prempro | $87 | $35,89955 claims |
| Boehringer IngelheimJardiance | $210 | $29,36835 claims |
| Lilly USA, LLCMounjaro, Trulicity | $44 | $26,58123 claims |
| GSKTrelegy Ellipta | $32 | $9,07814 claims |
| AstraZenecaSymbicort | $15 | $4,87521 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Lawton
- Carl GriffinOklahoma City$28.2M
- Lisa ConneryNorman$15.6M
- Kyle RicknerYukon$14.7M
- Robert LockwoodYukon$8.6M
- Steven CoxNorman$6.9M
- Alexander FrankOklahoma City$3.1M
- Rachel AndersonNorman$2.8M
- Robert WestcottLindsay$1.6M
- Charles LunnOklahoma City$1.4M
- Jeffrey ChasteenTulsa$820K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.